{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:14Z","timestamp":1791994574149,"version":"4.4.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10787-025-02079-0","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:49:20Z","timestamp":1765810160000},"page":"145-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A systematic review of therapeutic and paradoxical roles of tumor necrosis factor \u03b1 inhibitors in autoimmune blistering diseases"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-4066","authenticated-orcid":false,"given":"Yekta","family":"Ghane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5239-7967","authenticated-orcid":false,"given":"Ali","family":"Ezzatollahi Tanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-9385","authenticated-orcid":false,"given":"Mina","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5576-998X","authenticated-orcid":false,"given":"Negar","family":"Ghotbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-7154","authenticated-orcid":false,"given":"Fateme","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-9897","authenticated-orcid":false,"given":"Asma","family":"Rasouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2079_CR1","doi-asserted-by":"publisher","first-page":"e35317","DOI":"10.7759\/cureus.35317","volume":"15","author":"H Alshehri","year":"2023","unstructured":"Alshehri H et al (2023) Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab. Cureus. 15:e35317. https:\/\/doi.org\/10.7759\/cureus.35317","journal-title":"Cureus."},{"key":"2079_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5152\/tjr.2010.31","volume":"25","author":"O Altindag","year":"2010","unstructured":"Altindag O et al (2010) A Case with Anti TNF- \u03b1 Induced Bullous Pemhigoid. Turkish J Rheumatology. 25:214\u2013216. https:\/\/doi.org\/10.5152\/tjr.2010.31","journal-title":"Turkish J Rheumatology."},{"key":"2079_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8807","author":"S Al-Zahawi","year":"2024","unstructured":"Al-Zahawi S et al (2024) A case of IgA pemphigus, with a poor response to dapsone, successfully treated with adalimumab. Clinical Case Reports. https:\/\/doi.org\/10.1002\/ccr3.8807","journal-title":"Clinical Case Reports"},{"key":"2079_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/1735-1995.156182","volume":"20","author":"TS Andres","year":"2015","unstructured":"Andres TS et al (2015) Etanercept plus methotrexate: An effective combination therapy for recalcitrant pemphigus vulgaris. J Res Med Sci 20:317","journal-title":"J Res Med Sci"},{"key":"2079_CR5","unstructured":"Berbert Ferreira, S., et al. 2020 Onset of bullous pemphigoid during psoriasis treatment with etanercept and remission with ustekinumab. J Dermatology Nurses\u2019 Association 12:"},{"key":"2079_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000243805","volume":"219","author":"M Bordignon","year":"2009","unstructured":"Bordignon M et al (2009) Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 219:357\u2013358. https:\/\/doi.org\/10.1159\/000243805","journal-title":"Dermatology"},{"key":"2079_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L et al (2022) Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 36:1689\u20131704. https:\/\/doi.org\/10.1111\/jdv.18220","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2079_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000318008","volume":"221","author":"L Boussemart","year":"2010","unstructured":"Boussemart L et al (2010) Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 221:201\u2013205. https:\/\/doi.org\/10.1159\/000318008","journal-title":"Dermatology"},{"key":"2079_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jdcr.2016.09.002","volume":"2","author":"KD Bryant","year":"2016","unstructured":"Bryant KD et al (2016) Linear IgA dermatosis after infliximab infusion for ulcerative colitis. JAAD Case Rep. 2:448\u2013450. https:\/\/doi.org\/10.1016\/j.jdcr.2016.09.002","journal-title":"JAAD Case Rep."},{"key":"2079_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","volume":"142","author":"MJ Canizares","year":"2006","unstructured":"Canizares MJ et al (2006) Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 142:1457\u20131461. https:\/\/doi.org\/10.1001\/archderm.142.11.1457","journal-title":"Arch Dermatol"},{"key":"2079_CR11","doi-asserted-by":"publisher","first-page":"e42791","DOI":"10.7759\/cureus.42791","volume":"15","author":"A Chokshi","year":"2023","unstructured":"Chokshi A et al (2023) Paradoxical Tumor Necrosis Factor-Alpha (TNF-\u03b1) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment. Cureus. 15:e42791. https:\/\/doi.org\/10.7759\/cureus.42791","journal-title":"Cureus."},{"key":"2079_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137018","author":"D Costin","year":"2024","unstructured":"Costin D et al (2024) Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors. Int J Molecular Sci. https:\/\/doi.org\/10.3390\/ijms25137018","journal-title":"Int J Molecular Sci"},{"key":"2079_CR13","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.0970","volume":"20","author":"F Cusano","year":"2010","unstructured":"Cusano F et al (2010) Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Eur J Dermatol 20:520. https:\/\/doi.org\/10.1684\/ejd.2010.0970","journal-title":"Eur J Dermatol"},{"key":"2079_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1468-3083.2008.02929.x","volume":"23","author":"S Daulat","year":"2009","unstructured":"Daulat S et al (2009) Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 23:483\u2013484. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02929.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2079_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103332","volume":"22","author":"L De Stefano","year":"2023","unstructured":"De Stefano L et al (2023) Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun Rev 22:103332. https:\/\/doi.org\/10.1016\/j.autrev.2023.103332","journal-title":"Autoimmun Rev"},{"key":"2079_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14201","volume":"33","author":"D Didona","year":"2020","unstructured":"Didona D et al (2020) Erythromycin-induced pemphigus foliaceus successfully treated with etanercept. Dermatol Ther 33:e14201. https:\/\/doi.org\/10.1111\/dth.14201","journal-title":"Dermatol Ther"},{"key":"2079_CR17","doi-asserted-by":"publisher","unstructured":"Driscoll, C. B., et al. (2025) Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis. Cancers 17, https:\/\/doi.org\/10.3390\/cancers17030390","DOI":"10.3390\/cancers17030390"},{"key":"2079_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","volume":"145","author":"S Egami","year":"2020","unstructured":"Egami S et al (2020) Autoimmune bullous skin diseases, pemphigus and pemphigoid. J Allergy Clin Immunol 145:1031\u20131047. https:\/\/doi.org\/10.1016\/j.jaci.2020.02.013","journal-title":"J Allergy Clin Immunol"},{"key":"2079_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C et al (2015) Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 172:867\u2013877. https:\/\/doi.org\/10.1111\/bjd.13717","journal-title":"Br J Dermatol"},{"key":"2079_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/archdermatol.2010.409","volume":"147","author":"DF Fiorentino","year":"2011","unstructured":"Fiorentino DF et al (2011) A pilot study of etanercept treatment for pemphigus vulgaris. Arch Dermatol 147:117\u2013118. https:\/\/doi.org\/10.1001\/archdermatol.2010.409","journal-title":"Arch Dermatol"},{"key":"2079_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.05.029","volume":"67","author":"A Garcia-Rabasco","year":"2012","unstructured":"Garcia-Rabasco A et al (2012) Infliximab therapy failure in two patients with pemphigus vulgaris. J Am Acad Dermatol 67:e196-197. https:\/\/doi.org\/10.1016\/j.jaad.2011.05.029","journal-title":"J Am Acad Dermatol"},{"key":"2079_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ijd.14686","volume":"59","author":"FT Gibson","year":"2020","unstructured":"Gibson FT, Amber KT (2020) Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review. Int J Dermatol 59:520\u2013524. https:\/\/doi.org\/10.1111\/ijd.14686","journal-title":"Int J Dermatol"},{"key":"2079_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/pde.15301","volume":"40","author":"V Gruber","year":"2023","unstructured":"Gruber V et al (2023) Bullous pemphigoid as a precursor of Crohn\u2019s disease in an 11-year-old boy. Pediatr Dermatol 40:27\u201328. https:\/\/doi.org\/10.1111\/pde.15301","journal-title":"Pediatr Dermatol"},{"key":"2079_CR24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2006.08.041","volume":"55","author":"E Gubinelli","year":"2006","unstructured":"Gubinelli E et al (2006) Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol 55:1107\u20131108. https:\/\/doi.org\/10.1016\/j.jaad.2006.08.041","journal-title":"J Am Acad Dermatol"},{"key":"2079_CR25","doi-asserted-by":"publisher","first-page":"AB115","DOI":"10.1016\/j.jaad.2012.12.478","volume":"68","author":"F Guimera-Martin-Neda","year":"2013","unstructured":"Guimera-Martin-Neda F et al (2013) Treatment of coexisting pemphigus foliaceus and psoriasis with adalimumab. J Am Academy of Dermatology 68:AB115. https:\/\/doi.org\/10.1016\/j.jaad.2012.12.478","journal-title":"J Am Academy of Dermatology"},{"issue":"3","key":"2079_CR26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjd.13350","volume":"172","author":"RP Hall","year":"2015","unstructured":"Hall RP et al (2015) A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol 172(3):760\u2013768. https:\/\/doi.org\/10.1111\/bjd.13350","journal-title":"Br J Dermatol"},{"key":"2079_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814429","author":"B He","year":"2022","unstructured":"He B et al (2022) The risk of adverse effects of TNF-\u03b1 inhibitors in patients with rheumatoid arthritis: a network meta-analysis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.814429","journal-title":"Front Immunol"},{"key":"2079_CR28","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","volume":"142","author":"MP Heffernan","year":"2006","unstructured":"Heffernan MP, Bentley DD (2006) Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 142:1268\u20131270. https:\/\/doi.org\/10.1001\/archderm.142.10.1268","journal-title":"Arch Dermatol"},{"key":"2079_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000431172","volume":"231","author":"J Hoffmann","year":"2015","unstructured":"Hoffmann J et al (2015) Linear IgA bullous dermatosis secondary to infliximab therapy in a patient with ulcerative colitis. Dermatology 231:112\u2013115. https:\/\/doi.org\/10.1159\/000431172","journal-title":"Dermatology"},{"key":"2079_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000489163","volume":"10","author":"S Hoffmann","year":"2018","unstructured":"Hoffmann S et al (2018) Bullous pemphigoid associated with adalimumab therapy in a patient with ulcerative colitis. Case Rep Dermatol 10:145\u2013148. https:\/\/doi.org\/10.1159\/000489163","journal-title":"Case Rep Dermatol"},{"key":"2079_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501163","volume":"100","author":"CMA Honorato","year":"2025","unstructured":"Honorato CMA et al (2025) Bullous pemphigoid: epidemiological, clinical, and therapeutic analysis of 189 patients in a tertiary center in Brazil. An Bras Dermatol 100:501163. https:\/\/doi.org\/10.1016\/j.abd.2025.501163","journal-title":"An Bras Dermatol"},{"key":"2079_CR32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2005.02.051","volume":"53","author":"SM Howell","year":"2005","unstructured":"Howell SM et al (2005) Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 53:541\u2013543. https:\/\/doi.org\/10.1016\/j.jaad.2005.02.051","journal-title":"J Am Acad Dermatol"},{"key":"2079_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","volume":"153","author":"A Jacobi","year":"2005","unstructured":"Jacobi A et al (2005) Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 153:448\u2013449. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06744.x","journal-title":"Br J Dermatol"},{"key":"2079_CR34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/sj.eye.6702948","volume":"21","author":"H John","year":"2007","unstructured":"John H et al (2007) Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-\u03b1. Eye (Lond) 21:1434\u20131435. https:\/\/doi.org\/10.1038\/sj.eye.6702948","journal-title":"Eye (Lond)"},{"key":"2079_CR35","doi-asserted-by":"crossref","unstructured":"Judith Lammer, R. H., Sophie Roenneberg, Tilo Biedermann and Thomas Volz 2019 Drug-induced Linear IgA Bullous Dermatosis: a Case Report and Review of the Literature Acta Derm Venereol","DOI":"10.2340\/00015555-3154"},{"key":"2079_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13801","volume":"33","author":"H Kaya Erdogan","year":"2020","unstructured":"Kaya Erdogan H et al (2020) Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: a case report. Dermatol Ther 33:e13801. https:\/\/doi.org\/10.1111\/dth.13801","journal-title":"Dermatol Ther"},{"key":"2079_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2340\/00015555-1658","volume":"94","author":"JS Kern","year":"2014","unstructured":"Kern JS et al (2014) Overlap of IgA pemphigus and linear IgA dermatosis in a patient with ulcerative colitis: a mere coincidence? Acta Derm Venereol 94:228\u2013230. https:\/\/doi.org\/10.2340\/00015555-1658","journal-title":"Acta Derm Venereol"},{"key":"2079_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1365-2230.2011.04102.x","volume":"36","author":"J Kluk","year":"2011","unstructured":"Kluk J et al (2011) Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol 36:871\u2013873. https:\/\/doi.org\/10.1111\/j.1365-2230.2011.04102.x","journal-title":"Clin Exp Dermatol"},{"key":"2079_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/DAD.0000000000002352","volume":"45","author":"BD Kwinta","year":"2023","unstructured":"Kwinta BD et al (2023) Drug-induced linear IgA bullous dermatosis mimicking Stevens\u2013Johnson syndrome treated with etanercept: a case report. Am J Dermatopathol 45:189\u2013191. https:\/\/doi.org\/10.1097\/DAD.0000000000002352","journal-title":"Am J Dermatopathol"},{"key":"2079_CR40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee HH et al (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-? antagonists. Br J Dermatol 156:486\u2013491. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07682.x","journal-title":"Br J Dermatol"},{"key":"2079_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16286","volume":"34","author":"T Li","year":"2020","unstructured":"Li T et al (2020) Treatment\u2010resistant bullous pemphigoid occurring under antitumour necrosis factor\u2010\u03b1 agent therapy in a patient with ulcerative colitis: a case report. J Eur Acad Dermatol Venereol 34:e324-e326. https:\/\/doi.org\/10.1111\/jdv.16286","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2079_CR42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1001\/archderm.141.6.680","volume":"141","author":"MH Lin","year":"2005","unstructured":"Lin MH (2005) Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 141:680\u2013682. https:\/\/doi.org\/10.1001\/archderm.141.6.680","journal-title":"Arch Dermatol"},{"key":"2079_CR43","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/ddg.15232","volume":"21","author":"JJ Lluch-Galcer\u00e1","year":"2023","unstructured":"Lluch-Galcer\u00e1 JJ et al (2023) Refractory IgA pemphigus successfully managed with adalimumab as monotherapy. JDDG: Journal der deutschen Dermatologischen Gesellschaft 21:1560\u20131562. https:\/\/doi.org\/10.1111\/ddg.15232","journal-title":"JDDG: Journal der deutschen Dermatologischen Gesellschaft"},{"key":"2079_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04673-0","author":"DN Lopes","year":"2024","unstructured":"Lopes DN et al (2024) Co-occurrence of oral pemphigus vulgaris and herpes simplex virus infection in a young patient with Crohn\u2019s disease: report of a rare case of oral lesions during anti-TFN alpha and immunomodulator therapy. Int J Colorectal Dis. https:\/\/doi.org\/10.1007\/s00384-024-04673-0","journal-title":"Int J Colorectal Dis"},{"key":"2079_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098187","volume":"24","author":"L Lopetuso","year":"2023","unstructured":"Lopetuso L et al (2023) Focus on anti-Tumour necrosis factor (TNF)-\u03b1-related autoimmune diseases. Int J Mol Sci 24:8187. https:\/\/doi.org\/10.3390\/ijms24098187","journal-title":"Int J Mol Sci"},{"key":"2079_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100211","volume":"7","author":"J Lu","year":"2023","unstructured":"Lu J, Lu Y (2023) Paradoxical psoriasis: the flip side of idiopathic psoriasis or an autocephalous reversible drug reaction? J Transl Autoimmun 7:100211. https:\/\/doi.org\/10.1016\/j.jtauto.2023.100211","journal-title":"J Transl Autoimmun"},{"key":"2079_CR47","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bjd.12163","volume":"168","author":"Y Majima","year":"2013","unstructured":"Majima Y et al (2013) A successful treatment with ustekinumab in a case of antilaminin-\u03b31 pemphigoid associated with psoriasis: correspondence. Br J Dermatol 168:1367\u20131369. https:\/\/doi.org\/10.1111\/bjd.12163","journal-title":"Br J Dermatol"},{"key":"2079_CR48","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/1346-8138.12171","volume":"40","author":"M Mochizuki","year":"2013","unstructured":"Mochizuki M et al (2013) Pemphigoid nodularis possibly induced by etanercept. J Dermatol 40:578\u2013579. https:\/\/doi.org\/10.1111\/1346-8138.12171","journal-title":"J Dermatol"},{"key":"2079_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jaad.2013.09.037","volume":"70","author":"AC Moreno","year":"2014","unstructured":"Moreno AC et al (2014) IgA pemphigus: case series with emphasis on therapeutic response. J Am Acad Dermatol 70:200\u2013201. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.037","journal-title":"J Am Acad Dermatol"},{"key":"2079_CR50","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH et al (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"key":"2079_CR51","unstructured":"National Heart, L., and Blood Institute 2014 Quality Assessment of Clinical trials"},{"key":"2079_CR52","unstructured":"National Heart, L., and Blood Institute 2014 Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group"},{"key":"2079_CR53","unstructured":"National Heart, L., and Blood Institute 2014 Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies"},{"key":"2079_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1346-8138.2012.01659.x","volume":"40","author":"M Nin","year":"2013","unstructured":"Nin M et al (2013) Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 40:55\u201356. https:\/\/doi.org\/10.1111\/j.1346-8138.2012.01659.x","journal-title":"J Dermatol"},{"key":"2079_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/24725625.2018.1468235","volume":"2","author":"N Ohkubo","year":"2018","unstructured":"Ohkubo N et al (2018) Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid\/methotrexate-resistant pemphigus erythematosus. Mod Rheumatol Case Rep 2:137\u2013142. https:\/\/doi.org\/10.1080\/24725625.2018.1468235","journal-title":"Mod Rheumatol Case Rep"},{"key":"2079_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2079_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2133.2005.06672.x","volume":"153","author":"J Pardo","year":"2005","unstructured":"Pardo J et al (2005) Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 153:222\u2013223. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06672.x","journal-title":"Br J Dermatol"},{"key":"2079_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-025-04305-5","author":"Y Piao","year":"2025","unstructured":"Piao Y et al (2025) Paradoxical psoriasis in pediatric tumor necrosis factor-\u03b1 inhibitor therapy database. Pediatric Res. https:\/\/doi.org\/10.1038\/s41390-025-04305-5","journal-title":"Pediatric Res"},{"key":"2079_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2340\/00015555-0132","volume":"87","author":"S Prey","year":"2007","unstructured":"Prey S et al (2007) Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol 87:74\u201375. https:\/\/doi.org\/10.2340\/00015555-0132","journal-title":"Acta Derm Venereol"},{"key":"2079_CR60","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjd.15400","volume":"178","author":"M Prieto-Barrios","year":"2018","unstructured":"Prieto-Barrios M et al (2018) Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. Br J Dermatol 178:786\u2013789. https:\/\/doi.org\/10.1111\/bjd.15400","journal-title":"Br J Dermatol"},{"key":"2079_CR61","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00384-014-1924-9","volume":"29","author":"M Ricci","year":"2014","unstructured":"Ricci M et al (2014) <article-title update=\u201cadded\u201d>Bullous pemphigoid occurring under anti-tumor necrosis factor-\u03b1 therapy. Int J Colorectal Dis 29:1573\u20131574. https:\/\/doi.org\/10.1007\/s00384-014-1924-9","journal-title":"Int J Colorectal Dis"},{"key":"2079_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1159351","author":"M Rosi-Schumacher","year":"2023","unstructured":"Rosi-Schumacher M et al (2023) Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1159351","journal-title":"Front Immunol"},{"key":"2079_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1067\/mjd.2001.119100","volume":"46","author":"C Sacher","year":"2002","unstructured":"Sacher C et al (2002) Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor \u03b1 antagonist etanercept. J Am Acad Dermatol 46:113\u2013115. https:\/\/doi.org\/10.1067\/mjd.2001.119100","journal-title":"J Am Acad Dermatol"},{"key":"2079_CR64","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2230.2007.02603.x","volume":"33","author":"R Saraceno","year":"2008","unstructured":"Saraceno R et al (2008) A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol 33:154\u2013155. https:\/\/doi.org\/10.1111\/j.1365-2230.2007.02603.x","journal-title":"Clin Exp Dermatol"},{"key":"2079_CR65","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1365-4632.2010.04707.x","volume":"50","author":"S Schulz","year":"2011","unstructured":"Schulz S et al (2011) Therapeutic effect of etanercept in anti-laminin 5 (laminin 332) mucous membrane pemphigoid. Int J Dermatol 50:1129\u20131131. https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04707.x","journal-title":"Int J Dermatol"},{"key":"2079_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2024.07.002","volume":"138","author":"G Setti","year":"2024","unstructured":"Setti G et al (2024) Anti-TNF-\u03b1 induced mucous membrane pemphigoid-like disease. Oral Surg Oral Med Oral Pathol Oral Radiol 138:e95-e100. https:\/\/doi.org\/10.1016\/j.oooo.2024.07.002","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2079_CR67","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1111\/j.1365-2230.2008.03204.x","volume":"34","author":"B Stausbol-Gron","year":"2009","unstructured":"Stausbol-Gron B et al (2009) Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 34:e285-286. https:\/\/doi.org\/10.1111\/j.1365-2230.2008.03204.x","journal-title":"Clin Exp Dermatol"},{"key":"2079_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15770","volume":"48","author":"M Sugaya","year":"2021","unstructured":"Sugaya M et al (2021) Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. J Dermatol 48:e163-e164. https:\/\/doi.org\/10.1111\/1346-8138.15770","journal-title":"J Dermatol"},{"key":"2079_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1214011","author":"K Szyma\u0144ski","year":"2023","unstructured":"Szyma\u0144ski K et al (2023) Case report: biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1214011","journal-title":"Front Immunol"},{"key":"2079_CR70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1684\/ejd.2018.3431","volume":"29","author":"N Tani","year":"2019","unstructured":"Tani N et al (2019) Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis. Eur J Dermatol 29:88\u201390. https:\/\/doi.org\/10.1684\/ejd.2018.3431","journal-title":"Eur J Dermatol"},{"key":"2079_CR71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/idoj.IDOJ_53_19","volume":"11","author":"A Tirado-Sanchez","year":"2020","unstructured":"Tirado-Sanchez A, Bonifaz A (2020) Simultaneous bullous pemphigoid and vitiligo associated with adalimumab therapy in a patient with psoriasis vulgaris. Indian Dermatol Online J 11:229\u2013231. https:\/\/doi.org\/10.4103\/idoj.IDOJ_53_19","journal-title":"Indian Dermatol Online J"},{"key":"2079_CR72","doi-asserted-by":"publisher","first-page":"676","DOI":"10.23736\/S2784-8671.24.07911-8","volume":"159","author":"E Trovato","year":"2024","unstructured":"Trovato E et al (2024) Bullous pemphigoid induced by adalimumab in a patient with psoriasis. Italian J Dermatology Venereology. 159:676\u2013677. https:\/\/doi.org\/10.23736\/S2784-8671.24.07911-8","journal-title":"Italian J Dermatology Venereology."},{"key":"2079_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13466","volume":"62","author":"M van Ammers","year":"2021","unstructured":"van Ammers M et al (2021) Bullous pemphigoid in a young male during treatment with adalimumab. Australas J Dermatol 62:e155-e156. https:\/\/doi.org\/10.1111\/ajd.13466","journal-title":"Australas J Dermatol"},{"key":"2079_CR74","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1590\/abd1806-4841.20131949","volume":"88","author":"TJ Vargas","year":"2013","unstructured":"Vargas TJ et al (2013) Linear IgA dermatosis associated with ulcerative colitis: complete and sustained remission after total colectomy. An Bras Dermatol 88:600\u2013603. https:\/\/doi.org\/10.1590\/abd1806-4841.20131949","journal-title":"An Bras Dermatol"},{"key":"2079_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1529-8019.2012.01433.x","volume":"25","author":"N Vojackova","year":"2012","unstructured":"Vojackova N et al (2012) Pemphigus vulgaris treated with adalimumab: case study. Dermatol Ther 25:95\u201397. https:\/\/doi.org\/10.1111\/j.1529-8019.2012.01433.x","journal-title":"Dermatol Ther"},{"key":"2079_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bjd\/ljad113.040","volume":"188","author":"E Wasson","year":"2023","unstructured":"Wasson E et al (2023) P12 A flare of dermatitis herpetiformis precipitated by etanercept. Br J Dermatol 188:19\u201320. https:\/\/doi.org\/10.1093\/bjd\/ljad113.040","journal-title":"Br J Dermatol"},{"key":"2079_CR77","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jdcr.2017.03.008","volume":"3","author":"LL Wessman","year":"2017","unstructured":"Wessman LL et al (2017) Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis. JAAD Case Rep 3:339\u2013341. https:\/\/doi.org\/10.1016\/j.jdcr.2017.03.008","journal-title":"JAAD Case Rep"},{"key":"2079_CR78","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000597712.90740.16","volume":"114","author":"KN Williams","year":"2019","unstructured":"Williams KN et al (2019) 2045\u2003Linear IgA bullous dermatosis is an unusual skin extra-intestinal manifestation in IBD. Am J Gastroenterol 114:S1145-S1145. https:\/\/doi.org\/10.14309\/01.ajg.0000597712.90740.16","journal-title":"Am J Gastroenterol"},{"key":"2079_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jdcr.2015.12.006","volume":"2","author":"EN Wilmer","year":"2016","unstructured":"Wilmer EN et al (2016) Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep 2:25\u201327. https:\/\/doi.org\/10.1016\/j.jdcr.2015.12.006","journal-title":"JAAD Case Rep"},{"key":"2079_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847160","author":"W Xie","year":"2022","unstructured":"Xie W et al (2022) Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.847160","journal-title":"Front Immunol"},{"key":"2079_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000355354","volume":"227","author":"S Yamada","year":"2013","unstructured":"Yamada S et al (2013) Association of linear IgA bullous disease with ulcerative colitis: a case of successful treatment with infliximab. Dermatology 227:295\u2013298. https:\/\/doi.org\/10.1159\/000355354","journal-title":"Dermatology"},{"key":"2079_CR82","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/ijd.IJD_794_19","volume":"66","author":"K Yamada","year":"2021","unstructured":"Yamada K et al (2021) Superimposed effects of adalimumab and linagliptin on the development of bullous pemphigoid in a psoriatic patient: a case report. Indian J Dermatol 66:208\u2013210. https:\/\/doi.org\/10.4103\/ijd.IJD_794_19","journal-title":"Indian J Dermatol"},{"key":"2079_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.055","volume":"54","author":"PS Yamauchi","year":"2006","unstructured":"Yamauchi PS et al (2006) Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 54:S121-122. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.055","journal-title":"J Am Acad Dermatol"},{"key":"2079_CR84","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036988","volume":"103","author":"L Yao","year":"2024","unstructured":"Yao L et al (2024) Adalimumab induced exacerbation of psoriasis in patients with combined pemphigus A case report. Medicine 103:E36988. https:\/\/doi.org\/10.1097\/MD.0000000000036988","journal-title":"Medicine"},{"key":"2079_CR85","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.2169\/internalmedicine.4646-20","volume":"59","author":"N Yoshikawa","year":"2020","unstructured":"Yoshikawa N et al (2020) <article-title update=\u201cadded\u201d>Drug-induced bullous pemphigoid and lupus erythematosus occurring under anti-TNF-\u03b1 and IL-6 therapy in a patient with rheumatoid arthritis. Intern Med 59:2611\u20132618. https:\/\/doi.org\/10.2169\/internalmedicine.4646-20","journal-title":"Intern Med"},{"key":"2079_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050373","author":"J Zhang","year":"2023","unstructured":"Zhang J et al (2023) Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1050373","journal-title":"Front Immunol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02079-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:26:44Z","timestamp":1769704004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02079-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2079"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02079-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article is a review of previously published studies and does not involve human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}